Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.39 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535142 | 0.85 | ACLY (0.47) | EGLN1MAPTALDH1A1LMNAKDM4E | |
| SCHEMBL5348731 | 0.79 | TAAR1 (0.50) | MAPTALDH1A1LMNAL3MBTL1GAA | |
| SCHEMBL11532393 | 0.77 | MAPT (0.57) | MAPTEGFRALDH1A1POLBGAA | |
| SCHEMBL12808519 | 0.76 | NPSR1 (0.61) | MAPTCCNCCDK8ALDH1A1LMNA | |
| SCHEMBL5582368 | 0.76 | HPGD (0.50) | CYP11B1CYP11B2MAPTEGFRALDH1A1 | |
| SCHEMBL12370801 | 0.75 | HRH3 (0.49) | MAPT | |
| SCHEMBL2355633 | 0.74 | SHMT1 (0.41) | ALDH1A1KDM4ESCN2ASCN10A | |
| SCHEMBL509730 | 0.74 | SUCNR1 (0.50) | ALDH1A1KDM4E | |
| SCHEMBL14609800 | 0.74 | MAPT (0.54) | CYP11B1CYP11B2MAPTEGFRALDH1A1 | |
| Cyclopropane SCHEMBL11849130 | 0.74 | MAPT (0.54) | MAPTEGFRALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130018202-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | BAYER CROPSCIENCE AG (DE) | 2013-01-17 | — | — | US | disclosed |
| US-8168566-B2 | 4-biphenyl-substituted pyrazolidin-3,5-dione derivatives | BAYER CROPSCIENCE AG (DE) | 2012-05-01 | — | — | US | disclosed |
| US-8119566-B2 | use as pesticides and/or herbicides and/or microbicides; for the selective control of weeds; synergistic; low application rates and concentrations; in particular in cereals (especially wheat) | BAYER CROPSCIENCE AG (DE) | 2012-02-21 | — | — | US | disclosed |
| US-20120040963-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | BAYER CROPSCIENCE AG (DE) | 2012-02-16 | — | — | US | disclosed |
| US-20080188371-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040963-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | DDT, CYP4X1, HPD | EGLN1 1066/4885CYP11B1 1201/4885CYP11B2 1283/4885 |
| US-20080188371-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | DDT, CYP4X1, HPD | EGLN1 1066/4885CYP11B1 1201/4885CYP11B2 1283/4885 |
| US-20130018202-A1 | 4-Biphenyl-Substituted Pyrazolidin-3,5-Dione Derivatives | DDT, CYP4X1, HPD | EGLN1 1066/4885CYP11B1 1201/4885CYP11B2 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.